Fig. 4From: Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort studySpironolactone persistence during the one-year follow up by disease cohort in the MRA population CKD chronic kidney disease, DKD diabetic kidney disease, HF heart failure, MRA mineralocorticoid receptor antagonistBack to article page